NEW YORK (GenomeWeb) – Intermountain Healthcare is offering a targeted next-generation sequencing-based panel internally to all patients with refractory cancer and will soon begin offering the service externally.

The Utah-based healthcare system has been offering the 100-gene panel internally for about one year, initially to refractory patients with gastrointestinal or lung cancer. It has now broadened its eligible patient base to all cancer patients with metastatic cancer, including those with solid tumors and blood-based cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.